CD63 and muscular dystrophy: The EVs of the patients with muscular dystrophy and those from unaffected individuals exhibited similar characteristics as demonstrated by their average size and amount using nanoparticle tracing analysis (Fig. S1A), by CD81 and CD9 expression as demonstrated by western blot analysis (Fig. S1B), and by CD63 and CD81 expression using enzyme-linked immunosorbent assay (ELISA) (Fig. S1C).